Overview

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Status:
Recruiting

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the efficacy, safety of camrelizumab in combination with nab-paclitaxel and famitinib in Patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast Cancer..

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel